Automatic tax sale by Opus Genetics (IRD) president limits trading signal

Rhea-AI Filing Summary

Opus Genetics, Inc. director and President Benjamin R. Yerxa reported an automatic sale of 7,429 shares of Common Stock on July 23, 2026 at $2.97 per share. The shares were automatically sold on his behalf, as required by the company, to satisfy tax withholding from a restricted stock unit vesting and settlement event, and the sale is described as not representing a discretionary trade. After this transaction, he directly holds 704,106 shares of Common Stock.

Insider Trade Summary

Net Seller: 7,429 shares

Net Sell 1 txn

Insider YERXA BENJAMIN R

Role President

Sold 7,429 shs ($22K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	7,429	$2.97	$22K

Holdings After Transaction: Common Stock — 704,106 shares (Direct)

Footnotes (1)

1. F1. The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person.

Key Figures

Shares sold: 7,429 shares Sale price: $2.97 per share Shares owned after sale: 704,106 shares

3 metrics

Shares sold 7,429 shares Automatic sale on July 23, 2026 to satisfy tax withholding obligations

Sale price $2.97 per share Price for Common Stock sold in the automatic tax-withholding transaction

Shares owned after sale 704,106 shares Direct Common Stock holdings of Benjamin R. Yerxa following the reported transaction

Key Terms

restricted stock units, tax withholding obligations, discretionary trade, vesting and settlement event

4 terms

restricted stock units financial

"arose in connection with a vesting and settlement event from a restricted stock units award"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"required by the Company to satisfy tax withholding obligations that arose in connection"

discretionary trade financial

"This transaction does not represent a discretionary trade by the Reporting Person"

vesting and settlement event financial

"arose in connection with a vesting and settlement event from a restricted stock units award"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/27/2026 - 04:08 PM Accepted by SEC EDGAR 07/27/2026 - 04:08 PM Learn about SEC filing dates

FAQ

What insider transaction did Opus Genetics (IRD) report for Benjamin R. Yerxa?

Benjamin R. Yerxa reported an automatic sale of 7,429 shares of Opus Genetics Common Stock. The shares were sold on July 23, 2026 at $2.97 per share to cover tax withholding triggered by a restricted stock unit vesting event.

Why were Benjamin R. Yerxa’s Opus Genetics (IRD) shares sold in this Form 4?

The 7,429 shares were sold automatically on Yerxa’s behalf to satisfy tax withholding obligations. These obligations arose from a vesting and settlement event of a restricted stock unit award and the sale is described as not being a discretionary trade.

How many Opus Genetics (IRD) shares does Benjamin R. Yerxa own after the reported sale?

Following the transaction, Benjamin R. Yerxa directly owns 704,106 shares of Opus Genetics Common Stock. This figure reflects his holdings after the automatic sale of 7,429 shares for tax withholding associated with an RSU vesting.

What price was received for the Opus Genetics (IRD) shares sold by Benjamin R. Yerxa?

The 7,429 shares of Opus Genetics Common Stock were sold at $2.97 per share. This per-share price applies to the automatic sale executed to cover tax withholding obligations linked to a restricted stock unit vesting event.

Was Benjamin R. Yerxa’s Opus Genetics (IRD) sale part of a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not marked, and a footnote explains the sale was automatic to satisfy tax withholding. The sale is specifically described as not representing a discretionary trade by the reporting person.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

YERXA BENJAMIN R

(Last) (First) (Middle)

C/O OPUS GENETICS, INC.

8 DAVIS DRIVE, SUITE 220

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Opus Genetics, Inc. [ IRD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/23/2026		S(1)		7,429	D	$2.97	704,106	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person.

	/s/ Amy Rabourn, by Power of Attorney	07/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)